This is a routine medical conference update with no material new data or regulatory catalyst. Monitor for any subsequent peer-reviewed publications or label expansion announcements, but no immediate trading action warranted.
AXSM drugs
AXSM drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 4 $231.48entry
- T+1 · 6mo ago +0.36%α +2.96% · $232.32
- T+5 · 5mo ago +9.63%α +12.18% · $253.77
- T+20 · 4mo ago +5.54%α +6.92% · $244.31
- T+60 · 3mo ago −14.02%α −15.90% · $199.02
Price Chart
How similar events traded
Executive Summary
Axsome Therapeutics announced presentations of new SYMBRAVO® data at the AHS 68th Annual Scientific Meeting, including post-hoc efficacy analyses and a network meta-analysis comparing SYMBRAVO to gepants for acute migraine treatment. This is a routine scientific conference update with no new regulatory or financial catalysts.
Key Facts
- Presentations at AHS 68th Annual Scientific Meeting, June 4-7 in Orlando, FL
- Four SYMBRAVO data presentations: post-hoc composite efficacy, network meta-analysis vs. gepants, sustained pain relief analysis, and safety endpoint analysis
- No new clinical trial results, regulatory decisions, or financial guidance provided
- SYMBRAVO is already FDA-approved for acute treatment of migraine
Financial Impact
No financial figures disclosed; routine scientific conference update
Risk Factors
- No new efficacy or safety signals disclosed that could change competitive positioning
- Network meta-analysis vs. gepants may not be considered definitive by prescribers
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306621 |
Track record
26 reports on AXSM
6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 2, 202614d ago 8-K Bullish 6/10 No price data
- Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
- Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
- Aug 10, 202614w ago 8-K Neutral 6/10 No price data
- Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
- Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
- Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
- Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
- Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers